- ISIN US74369R1005
- Country Deutschland
Latest Reports
News Functions
Additional Functions
9 November 2012
Proteo Biotech AG
Q3 report 2012
10 August 2012
Proteo Biotech AG
Q2 report 2012
15 May 2012
Proteo Biotech AG
Q1 report 2012
28 March 2012
Proteo Biotech AG
Annual Report 2011
7 November 2011
Proteo Biotech AG
Q3 report 2011
4 August 2011
Proteo Biotech AG
Q2 report 2011
16 May 2011
Proteo Biotech AG
Q1 report 2011
15 March 2011
Proteo Biotech AG
Annual Report 2010
12 November 2010
Proteo Biotech AG
Q3 report 2010
12 August 2010
Proteo Biotech AG
Q2 report 2010
17 May 2010
Proteo Biotech AG
Q1 report 2010
29 March 2010
Proteo Biotech AG
Annual Report 2009
5 November 2009
Proteo Biotech AG
Q3 report 2009
7 August 2009
Proteo Biotech AG
Q2 report 2009
11 May 2009
Proteo Biotech AG
Q1 report 2009
22 April 2009
Proteo Biotech AG
Annual Report 2008
3 November 2008
Proteo Biotech AG
Q3 report 2008
3 September 2008
Proteo Biotech AG
Q2 report 2008
21 May 2008
Proteo Biotech AG
Q1 report 2008
14 April 2008
Proteo Biotech AG
Annual Report 2007
15 November 2007
Proteo Biotech AG
Q3 report 2007
31 July 2007
Proteo Biotech AG
Q2 report 2007
16 May 2007
Proteo Biotech AG
Q1 report 2007
3 April 2007
Proteo Biotech AG
Annual Report 2006
14 December 2006
Proteo Biotech AG
Q3 report 2006
30 June 2006
Proteo Biotech AG
Q2 report 2006
30 March 2006
Proteo Biotech AG
Q1 report 2006
23 December 2005
Proteo Biotech AG
Annual Report 2005
14 November 2005
Proteo Biotech AG
Q3 report 2005
15 August 2005
Proteo Biotech AG
Q2 report 2005
Latest News
News Functions
Additional Functions
10 January 2013
Proteo Biotech AG
Proteo, Inc. / Proteo Biotech AG: FDA grants Proteo Orphan Drug Designation to Elafin for the treatment of pulmonary arterial hypertension
11 December 2012
Proteo Biotech AG
Proteo, Inc. / Proteo Biotech AG: Update for Phase 2 Study of Elafin in Coronary Bypass Surgery (EMPIRE Study)
27 June 2012
Proteo Biotech AG
Proteo, Inc. / Proteo Biotech AG: Further rationale for Elafin treatment in newborn infants – convincing preclinical evidence in a neonatal pulmonary model
22 June 2012
Proteo Biotech AG
Proteo, Inc. / Proteo Biotech AG: Update for Phase 2 Study of Elafin in Coronary Bypass Surgery (EMPIRE Study)
6 December 2011
Proteo Biotech AG
Proteo, Inc./Proteo Biotech AG: Major advances in the elafin development program for lung diseases – NIH supports research on Elafin with a $10.8 million grant
16 August 2011
Proteo Biotech AG
Proteo, Inc. / Proteo Biotech AG: EMPIRE-Study recruits first coronary bypass patients